Home›Research›Compare›CJC-1295 (without DAC) vs Tesamorelin
Peptide ComparisonCJC-1295 (without DAC) vs Tesamorelin
Both are GH / IGF Axis peptides.
CJC-1295 (without DAC)
CJC-1295
Half-life: ~30 minutes
446 providers listed
Tesamorelin
Egrifta
Half-life: 26–38 minutes
242 providers listed
Tesamorelin is FDA-approved, while CJC-1295 (without DAC) is nomination withdrawn — the clearest structural difference between them.
CJC-1295 (without DAC)
Evidence
Half-life
~30 minutes
Tesamorelin
Evidence
Half-life
26–38 minutes
| Your goal | Better option |
|---|---|
| Stronger clinical evidence | Tesamorelin |
| Further along in FDA review | Tesamorelin |
| More provider options (446 vs 242) | CJC-1295 (without DAC) |
Research summary only — not medical advice. Consult a qualified provider before making any decisions.
CJC-1295 (without DAC)
Tesamorelin
CJC-1295 (without DAC)
Tesamorelin
Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in HIV-infected patients with exce…
Effects of tesamorelin in HIV-infected patients with excess abdominal fat: pooled analysis of two phase 3 RCTs
Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications…
Combined antiretroviral therapy with low- or normal-protein, high-calorie diets appears to induce significant…
+3 more
About CJC-1295 (without DAC)
CJC-1295 without DAC (Mod GRF 1-29) is a short-acting GHRH analog that binds and activates pituitary GHRH receptors to stimulate brief, pulsatile growth hormone release. Lacking the Drug Affinity Complex, it is not albumin-bound and clears within roughly half an hour, producing discrete GH pulses rather than the sustained elevation of the DAC form.
About Tesamorelin
Tesamorelin stimulates pulsatile GH secretion from the anterior pituitary by binding GHRH receptors. Its stabilisation protects it from rapid enzymatic cleavage by dipeptidyl peptidase IV, extending the effective half-life compared to unmodified GHRH. Downstream effects on visceral adiposity are mediated through elevated IGF-1 and direct lipolytic signalling.
Information below reflects published research data only — not medical advice. Consult a qualified provider before use.
CJC-1295 (without DAC)
Class-based (investigational)
Research protocols routinely measure IGF-1 to track GH axis activity before and during use. Fasting glucose and insulin are monitored because GH elevation can reduce insulin sensitivity over time.
global — WADA
This compound falls under WADA Prohibited List category S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics), prohibited at all times for competing athletes.
sourceTesamorelin
Source: FDA label
Under clinical review
Being verified by our medical team before we display monitoring guidance for this peptide.
global — WADA
This compound falls under WADA Prohibited List category S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics), prohibited at all times for competing athletes.
sourceCJC-1295 (without DAC)
Ipamorelin
Research suggests Ipamorelin and CJC-1295 may produce enhanced growth hormone release effects when combined. CJC-1295 provides sustained GHRH receptor stimulation while Ipamorelin provides pulsatile ghrelin receptor stimulation — complementary pathways studied in GH secretion research.
GLP-1 agonists
Research notes metabolic pathway overlap between growth hormone-releasing peptides and GLP-1 agonists. Both compound classes influence metabolic signaling; limited research has studied their combined effects. Consult your prescriber before combining.
CJC-1295 (without DAC)
Tesamorelin
Where to source these peptides
CJC-1295 (without DAC)
446 listed
Browse directory →
Providers offeringTesamorelin
242 listed
Browse directory →
PeptideBase lists providers for educational research purposes only. Always consult a qualified healthcare professional before obtaining or using any peptide.
More GH / IGF Axis Comparisons
Browse all peptides →Educational research tools — not medical advice.
Cite this page
Data last updated July 22, 2026
Free to reference and republish with attribution to PeptideBase. Choose a format:
PeptideBase. (2026). CJC-1295 (without DAC) vs Tesamorelin — Per-mg Price Comparison. Retrieved July 22, 2026, from https://peptidebase.io/peptides/compare/cjc-1295/tesamorelin